Form D · Biotechnology

WindMIL Therapeutics, Inc.

Philadelphia, PA · CIK 0001671352

Offering snapshot reported Feb 5, 2021 · SEC filing

Reported sold
$2.33M
Offering amount: $5M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 26, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 5, 2021Initial$2,334,814No comparison11SEC filing
Jun 15, 2018Initial$32,525,358No comparison11SEC filing
Apr 7, 2016Initial$10,000,000No comparison4SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-388545
The total offering amount of $5,000,000 will be sold in two tranches. The first tranche equal to $2,334,814.78 of the total offering amount was sold on January 26, 2021. The remaining tranche will be sold upon the occurrence of certain events.

Source: Form D, filed Feb 5, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Brian Dovey Director
Patrick Fabbio Executive
Allan Fox Director
Anna French Director
Brian Halak Director, Executive
Donald J. Hayden, Jr. Director, Executive
Mark Mc Dade Director
Daniel O'donnell Director
Howard Soule Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3675 Market Street Suite 200
Philadelphia, PA, 19104